Welcome to our dedicated page for Dianthus Therapeutics news (Ticker: DNTH), a resource for investors and traders seeking the latest updates and insights on Dianthus Therapeutics stock.
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is a clinical-stage biotechnology company that regularly reports on progress in its programs for severe autoimmune and inflammatory diseases. News about Dianthus often centers on clinical trial milestones, data readouts, licensing transactions, and capital markets activity related to its investigational therapies.
The company’s updates frequently highlight developments for claseprubart (DNTH103), an investigational monoclonal antibody targeting the classical complement pathway via active C1s inhibition, and DNTH212, an investigational bifunctional fusion protein targeting BDCA2 and BAFF/APRIL. Press releases describe Phase 2 and Phase 3 studies in neuromuscular indications such as generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy, as well as early-stage work in systemic lupus erythematosus through a Phase 1 trial of DNTH212.
Investors and followers of DNTH news can expect coverage of clinical data presentations at medical meetings, initiation and progress of Phase 1, Phase 2, and Phase 3 trials, and regulatory milestones such as investigational new drug clearances. Company communications also include announcements of public offerings of common stock and pre-funded warrants, license and collaboration agreements with partners like Nanjing Leads Biolabs, and participation in healthcare and investor conferences.
This news feed aggregates these disclosures so readers can track how Dianthus advances its investigational complement and immune pathway therapies, how its pipeline evolves, and how financing and partnerships support ongoing development. For those monitoring DNTH, recurring themes include neuromuscular disease programs, complement biology, bifunctional immune modulation, and the company’s positioning as a clinical-stage biotech focused on severe autoimmune conditions.
Dianthus Therapeutics (Nasdaq: DNTH) will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York City.
CEO Marino Garcia will join an analyst-led fireside chat on Thursday, February 12, 2026 at 10:00 am EST and hold one-on-one investor meetings. A webcast will be available under "News and Events" in the Investors section of the Dianthus Therapeutics website.
Dianthus Therapeutics (Nasdaq: DNTH) announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. CEO Marino Garcia will present a corporate overview on Monday, January 12, 2026 at 3:00 pm PST / 6:00 pm EST and will hold one-on-one investor meetings.
A webcast of the presentation will be available in the company’s Investors section under “News and Events.” The announcement highlights investor access opportunities but does not provide financial or clinical data in this release.
Dianthus Therapeutics (Nasdaq: DNTH) and Leads Biolabs announced dosing of the first subject in the Phase 1 trial of LBL-047 (DNTH212) on Dec 23, 2025. The two-part, randomized, double-blind, placebo-controlled, single-ascending-dose study will evaluate safety, tolerability and PK/PD in healthy volunteers (Part A) and patients with systemic lupus erythematosus (Part B).
The bifunctional fusion protein targets pDC BDCA2 to reduce Type 1 interferon and inhibits BAFF/APRIL to suppress B cells. Leads and Dianthus formed an exclusive global partnership on Oct 16, 2025, with total potential deal value up to $1 billion; Dianthus holds rights outside Greater China. Top-line healthy-volunteer results are anticipated in 2H’26, and Dianthus will update indication prioritization in 1H’26.
Dianthus Therapeutics (Nasdaq: DNTH) will participate in the 8th Annual Evercore Healthcare Conference in Coral Gables, Florida. Marino Garcia, CEO, will join a fireside chat on December 2, 2025 at 2:35 p.m. ET and will hold one-on-one investor meetings.
A live webcast of the presentation may be accessed via the News and Events page in the Investors section of the Dianthus Therapeutics website.
Dianthus Therapeutics (Nasdaq: DNTH) reported Q3 2025 results and business updates highlighting positive clinical progress for claseprubart (DNTH103), the in-licensing of DNTH212, and a strengthened cash position. Key clinical developments include statistically significant Phase 2 MaGic gMG results at Week 13, AANEM data supporting potential 300mg/2mL Q4W dosing, planned Phase 3 gMG initiation in 2026 with two dose arms, accelerated CIDP Phase 3 interim responder analysis to Q2 2026, and ongoing MMN Phase 2 with top-line in 2H’26. Financial highlights: estimated adjusted cash of ~$525M (runway into 2028), R&D of $32.5M in Q3, and net loss of $36.8M (Q3 2025).
Dianthus Therapeutics (Nasdaq: DNTH) announced management will participate in four investor conferences in November 2025, offering fireside chats, one-on-one meetings and a corporate overview presentation.
CEO Marino Garcia will present at Guggenheim 2nd Annual Healthcare Innovation Conference in Boston on Nov 11, 2025 at 3:30 p.m. ET, at the ETTD Cowen Immunology & Inflammation Summit (virtual) on Nov 12, 2025 at 9:30 a.m. ET, at the Stifel 2025 Healthcare Conference in New York on Nov 13, 2025 at 2:00 p.m. ET, and will give a corporate overview at Jefferies Global Healthcare Conference in London on Nov 17, 2025 at 1:30 p.m. GMT. Webcasts will be available via the company Investors "News and Events" page.
Dianthus Therapeutics (Nasdaq: DNTH) presented new Phase 2 MaGic and preclinical data for claseprubart at the AANEM Annual Meeting and a virtual industry forum on Oct 29, 2025. Key clinical findings include an open-label extension (OLE) MG-ADL decline of -2.5 points at week 4 and a QMG reduction of -3.2 points for placebo-arm patients who received two 600mg/4mL Q2W doses. A post hoc subgroup with baseline QMG ≥10 showed a 3-point MG-ADL treatment difference for 300mg/2mL Q2W versus placebo. In vitro data suggested upstream (active C1s) inhibition may better prevent pro-inflammatory split products C3a/C3b versus C5 inhibition. Dianthus plans a Phase 3 gMG trial with two claseprubart arms (300mg/2mL Q2W and 300mg/2mL Q4W) versus placebo, anticipated to initiate in 2026.
Dianthus Therapeutics (Nasdaq: DNTH) entered an exclusive worldwide (ex-Greater China) license for DNTH212 from Leads Biolabs (LBL-047), a bifunctional BDCA2 & BAFF/APRIL inhibitor designed for severe autoimmune diseases.
Key facts: IND cleared by FDA in September 2025; Phase 1 expected to start in Q4 2025 with healthy-volunteer topline in 2H 2026. Dianthus paid $30M upfront/near-term and may pay up to $962M in milestones plus royalties. Pro forma cash ~$525M, company reaffirms runway into 2028.
Dianthus Therapeutics (NASDAQ:DNTH) announced upcoming presentations of its Phase 2 MaGic trial results for claseprubart in treating generalized Myasthenia Gravis (gMG) at the AANEM Annual Meeting in San Francisco. The presentations will take place on October 29, 2025.
The company will feature an oral presentation of the trial results during the MGFA Scientific Session and host a virtual industry forum titled "Upstream Targeting: Rethinking MG Treatment Through Active C1s Inhibition" featuring an expert panel of medical professionals. The forum will focus on the potential benefits of upstream inhibition in gMG treatment.
Dianthus Therapeutics (NASDAQ: DNTH), a clinical-stage biotech company, has successfully closed its upsized public offering, raising approximately $288 million in gross proceeds. The offering included 7,627,879 shares of common stock at $33.00 per share, with underwriters fully exercising their option for an additional 1,140,000 shares.
The company also offered pre-funded warrants for 1,112,121 shares at $32.999 per warrant with a $0.001 exercise price. The proceeds will support Dianthus's preclinical and clinical development activities, working capital, and general corporate purposes. The offering was managed by Jefferies, TD Cowen, Evercore ISI, and Stifel, with LifeSci Capital as lead manager.
FAQ
What is the current stock price of Dianthus Therapeutics (DNTH)?
What is the market cap of Dianthus Therapeutics (DNTH)?
